Increasing life expectancy in cystic fibrosis: Advances and challenges

被引：92

作者：

McBennett, Kimberly A. ^{[1
,2
]}

Davis, Pamela B. ^{[1
]}

Konstan, Michael W. ^{[1
,2
]}

机构：

[1] Case Western Reserve Univ, Sch Med, Cleveland, OH USA

[2] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA

来源：

PEDIATRIC PULMONOLOGY | 2022年 / 57卷

关键词：

CFTR modulators; cystic fibrosis; lung function; survival; TEZACAFTOR-IVACAFTOR; PSEUDOMONAS-CEPACIA; PULMONARY-FUNCTION; HISPANIC PATIENTS; DIAGNOSIS; OUTCOMES; COLONIZATION; LUMACAFTOR; GUIDELINES; IBUPROFEN;

D O I：

10.1002/ppul.25733

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Since the first description of cystic fibrosis in 1938, there have been significant advances in both quality of life and longevity for people living with this disease. In this article we describe the milestones of the last 80 years and what we perceive to be the remaining barriers to normalcy for this population.

引用

页码：S5 / S12

页数：8